Illumina, Inc. (ILMN) Shares Bought by State of Wisconsin Investment Board

State of Wisconsin Investment Board boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 19.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 185,505 shares of the life sciences company’s stock after buying an additional 29,943 shares during the period. State of Wisconsin Investment Board’s holdings in Illumina were worth $40,531,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of ILMN. Global X Management Co. LLC boosted its stake in Illumina by 61.5% during the 4th quarter. Global X Management Co. LLC now owns 4,150 shares of the life sciences company’s stock valued at $907,000 after purchasing an additional 1,581 shares during the last quarter. Toronto Dominion Bank boosted its stake in Illumina by 13.6% during the 4th quarter. Toronto Dominion Bank now owns 62,891 shares of the life sciences company’s stock valued at $13,740,000 after purchasing an additional 7,511 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Illumina by 0.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 156,610 shares of the life sciences company’s stock valued at $34,218,000 after purchasing an additional 1,292 shares during the last quarter. Barings LLC acquired a new position in Illumina during the 4th quarter valued at about $767,000. Finally, Sei Investments Co. boosted its stake in Illumina by 20.0% during the 4th quarter. Sei Investments Co. now owns 252,974 shares of the life sciences company’s stock valued at $55,272,000 after purchasing an additional 42,132 shares during the last quarter. 92.04% of the stock is owned by institutional investors and hedge funds.

In related news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $225.33, for a total value of $32,672.85. Following the transaction, the senior vice president now owns 6,388 shares in the company, valued at $1,439,408.04. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $211.35, for a total value of $4,227,000.00. Following the completion of the transaction, the director now owns 531,717 shares in the company, valued at approximately $112,378,387.95. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,440 shares of company stock worth $25,318,904. 0.89% of the stock is owned by company insiders.

Illumina, Inc. (NASDAQ ILMN) opened at $229.20 on Friday. Illumina, Inc. has a 12 month low of $158.02 and a 12 month high of $248.97. The firm has a market capitalization of $33,692.40, a P/E ratio of 57.16, a PEG ratio of 3.03 and a beta of 0.92. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.22. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The firm had revenue of $778.00 million for the quarter, compared to the consensus estimate of $752.04 million. During the same quarter in the previous year, the business earned $0.85 EPS. The company’s revenue was up 25.7% compared to the same quarter last year. research analysts forecast that Illumina, Inc. will post 4.59 earnings per share for the current fiscal year.

ILMN has been the subject of a number of analyst reports. Wells Fargo & Co upgraded Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price target for the company in a research note on Tuesday, January 2nd. Morgan Stanley lifted their price target on Illumina from $122.00 to $135.00 and gave the company an “underweight” rating in a research note on Thursday, December 14th. Citigroup lifted their price target on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research note on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $252.00 price target for the company in a research note on Tuesday, December 5th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $269.00 price target on shares of Illumina in a research note on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $241.39.

COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) Shares Bought by State of Wisconsin Investment Board” was first posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://weekherald.com/2018/02/18/illumina-inc-ilmn-shares-bought-by-state-of-wisconsin-investment-board.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply